Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition

Author(s): Jagannath Behera, Venkatesan Jayaprakash, Barij Nayan Sinha

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 15 , Issue 9 , 2015

Become EABM
Become Reviewer
Call for Editor


Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has summarized the inhibitors, based on their specificity towards different isoforms within this class. Further various recent United State (US) patents and the HDAC inhibitors, used singly or in combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer.

Keywords: Histone Deacetylase, cancer, isoform, Romidepsin, US-FDA.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 21 May, 2015
Page: [731 - 750]
Pages: 20
DOI: 10.2174/1389557515666150521162237
Price: $65

Article Metrics

PDF: 138
HTML: 12
PRC: 1